27-01-2022
Tada Images / Shutterstock.com
AstraZeneca has urged the US Court of Appeals for the Federal Circuit to revisit a split panel decision that breathed new life into Mylan’s bid to produce a generic version of the asthma inhaler, Symbicort Turbohaler.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
AstraZeneca, US Court of Appeals for the Federal Circuit, split panel decision, Mylan, generic, asthma inhaler, Symbicort Turbohaler, Kindeva
Generic drug maker fails to avoid inhaler patent lawsuit
14-07-2022
AstraZeneca says Mylan, Kindeva infringe another Symbicort patent
28-04-2022
AstraZeneca, MSD sue MSN and Sandoz over Calquence generics
08-02-2022
AstraZeneca inks $730m licensing deal for rare heart disease treatment
11-01-2022
AstraZeneca prevails in inhaler dispute
09-03-2021
